Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Beta haemolytic streptococcal infection? 53 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 53 reports of Beta haemolytic streptococcal infection have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.

53
Reports of Beta haemolytic streptococcal infection with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
2
Deaths
25
Hospitalizations

How Dangerous Is Beta haemolytic streptococcal infection From ADALIMUMAB?

Of the 53 reports, 2 (3.8%) resulted in death, 25 (47.2%) required hospitalization, and 2 (3.8%) were considered life-threatening.

Is Beta haemolytic streptococcal infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 53 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Beta haemolytic streptococcal infection?

IBUPROFEN (61) INFLIXIMAB (58) ACETAMINOPHEN (40) ETANERCEPT (35) PREDNISOLONE (34) PREDNISONE (27) METRONIDAZOLE (26) RITUXIMAB (26) METHOTREXATE (25) TACROLIMUS (25)

Which ADALIMUMAB Alternatives Have Lower Beta haemolytic streptococcal infection Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Beta haemolytic streptococcal infection Reports All Drugs Causing Beta haemolytic streptococcal infection ADALIMUMAB Demographics